Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NRx Pharmaceuticals Inc (NRXPW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: NRXPW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -80.14% | Avg. Invested days 18 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 714.61M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.55 | 52 Weeks Range 0.04 - 0.50 | Updated Date 05/27/2025 |
52 Weeks Range 0.04 - 0.50 | Updated Date 05/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.25 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -191.74% | Return on Equity (TTM) -682.61% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 13364027 |
Shares Outstanding - | Shares Floating 13364027 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
NRx Pharmaceuticals Inc
Company Overview
History and Background
NRx Pharmaceuticals Inc. is a biopharmaceutical company founded to address unmet needs in the treatment of psychiatric and neurological disorders, particularly those associated with suicidal ideation and other life-threatening conditions. Their focus is on developing novel therapeutics for diseases where existing treatments are insufficient or ineffective.
Core Business Areas
- NRx Pharmaceuticals: Focuses on the development and commercialization of therapeutics for the treatment of suicidal bipolar depression and other severe psychiatric disorders.
Leadership and Structure
The leadership team consists of experienced pharmaceutical executives and scientists. The organizational structure is designed to facilitate efficient drug development and regulatory approval processes.
Top Products and Market Share
Key Offerings
- NRx-101 (IV Ketamine + D-cycloserine): An investigational, patented, fixed-dose combination of intravenous ketamine and oral D-cycloserine to stabilize patients with suicidal ideation and bipolar depression. Currently, there is not clearly defined market share, but, current competitors includes drugs such as Lithium and Lamotrigine. NRx-101 represents a novel approach and seeks to address a significant unmet need. There are no specific market share figures publicly available for this specific product, but the overall market for depression treatments is substantial. The competitors for this are Janssen Pharmaceuticals and AbbVie.
- HTX-100 (Arimoclomol): An investigational oral formulation of arimoclomol for the treatment of Amyotrophic Lateral Sclerosis (ALS). The key competitor is Amylyx Pharmaceuticals (AMYX) with Relyvrio, which is FDA approved for the treatment of ALS. There is not clearly defined market share due to lack of FDA approval of HTX-100 for ALS.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, stringent regulatory requirements, and a competitive landscape. The psychiatric and neurological disorder segment is growing due to increasing awareness and diagnosis of these conditions.
Positioning
NRx Pharmaceuticals Inc. is positioned as an innovator in the treatment of severe psychiatric disorders. Their competitive advantage lies in their novel therapeutic approaches and their focus on unmet medical needs.
Total Addressable Market (TAM)
The TAM for psychiatric disorder treatments is substantial, estimated to be in the billions of dollars. NRx Pharmaceuticals Inc. aims to capture a significant share of this market by offering more effective treatments for specific conditions like suicidal bipolar depression and ALS.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approaches
- Focus on unmet medical needs
- Experienced leadership team
- Patented drug formulations
Weaknesses
- Limited commercialized products
- Dependence on clinical trial outcomes
- High cash burn rate
- Reliance on capital markets for funding
Opportunities
- Regulatory approvals for key drug candidates
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Increasing awareness and diagnosis of psychiatric disorders
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Changes in healthcare policies
Competitors and Market Share
Key Competitors
- JNJ
- ABBV
- AMYX
Competitive Landscape
NRx Pharmaceuticals Inc. faces competition from larger, established pharmaceutical companies with greater resources and broader product portfolios. Their competitive advantage lies in their novel therapeutic approaches and their focus on unmet medical needs.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by preclinical and clinical development progress. The company has not yet achieved significant commercial revenue.
Future Projections: Future growth is contingent on successful clinical trials and regulatory approvals. Analyst projections vary, reflecting the inherent risk in biopharmaceutical development.
Recent Initiatives: Recent initiatives include advancing clinical trials for NRx-101 and HTX-100, seeking partnerships, and exploring new indications for existing drug candidates.
Summary
NRx Pharmaceuticals is a high-risk, high-reward biopharmaceutical company focusing on unmet medical needs. Its future heavily relies on the success of clinical trials, particularly for NRx-101 and HTX-100. While the company has innovative therapeutic approaches, it faces significant financial challenges and strong competition. Investors should closely monitor clinical trial results and regulatory developments.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Press Releases
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not financial advice. Investors should conduct their own due diligence before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NRx Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Wilmington, DE, United States | ||
IPO Launch date 2017-12-01 | Co-Founder, Chief Scientist Officer, Chairman & Interim CEO Dr. Jonathan C. Javitt M.D., M.P.H. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.nrxpharma.com |
Full time employees - | Website https://www.nrxpharma.com | ||
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.